Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating restated by stock analysts at Noble Financial in a research note issued on Friday.

CRBP has been the subject of a number of other research reports. ValuEngine cut Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. BidaskClub upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $24.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $25.00.

Corbus Pharmaceuticals (CRBP) opened at $7.15 on Friday. Corbus Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $10.50.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The business had revenue of $0.80 million during the quarter. research analysts predict that Corbus Pharmaceuticals will post -0.61 EPS for the current year.

In other news, Director David P. Hochman acquired 5,000 shares of Corbus Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The stock was bought at an average price of $6.55 per share, for a total transaction of $32,750.00. Following the completion of the acquisition, the director now directly owns 459,500 shares in the company, valued at approximately $3,009,725. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David P. Hochman acquired 10,000 shares of Corbus Pharmaceuticals stock in a transaction dated Friday, November 10th. The shares were purchased at an average price of $7.08 per share, with a total value of $70,800.00. Following the acquisition, the director now owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Insiders have purchased 25,336 shares of company stock valued at $175,632 in the last quarter. 11.90% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Artal Group S.A. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth approximately $1,575,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth approximately $469,000. Alps Advisors Inc. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth approximately $286,000. Vanguard Group Inc. boosted its holdings in shares of Corbus Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock worth $10,357,000 after acquiring an additional 71,419 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Corbus Pharmaceuticals during the second quarter worth approximately $283,000. Institutional investors own 27.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/corbus-pharmaceuticals-crbp-rating-reiterated-by-noble-financial/1768955.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.